EUVIMEDEUVIMED entdecken
Kohortenstudie

The impact of cART on hepatic steatosis and fibrosis in treatment-naïve PLwHIV: A prospective cohort study

Meryem Sahin Ozdemir, Yusuf Emre Ozdemir iD, Alperen Dogdas, Kanan Nuriyev, Ibrahim Volkan Senkal, Alper Gunduz, Esra Zerdali, Sabahattin Kaymakoglu, Bilgul Mete iD, Fehmi Tabak iD

International Journal of STD & AIDS · 2026

DOI: 10.1177/09564624251382627 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift International Journal of STD & AIDS, 2026. Verfasst von Meryem Sahin Ozdemir und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Clinical Microbiology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Türkiye. Hauptthemen laut MEDLINE: Liver Cirrhosis, HIV Infections, Fatty Liver, Anti-HIV Agents. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Istanbul Üniversitesi-Cerrahpasa.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We aimed to determine the effect of combined antiretroviral therapy (cART) on hepatic steatosis and fibrosis in people living with human immunodeficiency virus (PLwHIV).

Methods

In this single-center and prospective cohort study, PLwHIV were evaluated longitudinally by transient elastography at the initiation and 7 months (±1 month) after the cART.

Results

Of the 81 PLwHIV, 28.3% had hepatic steatosis, 40.7% had fibrosis (≥F1), and 24.7% had significant fibrosis (≥F2). In multivariate analysis, body mass index (BMI) ( p = .005) and albumin ( p = .045) were independent predictors for hepatic steatosis, while aspartate aminotransferase (AST) ( p = .041) was an independent predictor for hepatic fibrosis. Control transient elastography was performed in 66 (81.5%) PLwHIV after treatment. Among these patients, the rate of hepatic fibrosis decreased significantly after treatment (43.9% vs 24.2%, p = .017). In the tenofovir alafenamide (TAF)-based regimen, weight ( p < .001), BMI ( p < .001), waist circumference ( p < .001), and total cholesterol ( p = .012) increased, while kPA value ( p = .002) decreased. In the tenofovir disoproxil fumarate (TDF)-based regimen, controlled attenuation parameter (CAP) value ( p = .017) and waist circumference ( p = .006) increased. In the lamivudine (LAM)-based regimen, there was no statistically significant change (p > .05).

Conclusion

Hepatic fibrosis regressed with antiretroviral treatments (especially with TAF-based), while the degree of hepatosteatosis progressed (especially with TDF-based). Additionally, weight gain occurred after cART in PLwHIV (especially with TAF-based). Therefore, hepatic steatosis and weight gain in PLwHIV should not be disregarded. In conclusion, PLwHIV on cART need close follow-up for the development of metabolic complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisHIV InfectionsFatty LiverAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveHumansMaleFemaleProspective StudiesElasticity Imaging TechniquesAdultMiddle AgedBody Mass IndexTreatment OutcomeTenofovirAspartate Aminotransferases

Stichwörter der Autor:innen

AIDSHIVNAFLDcontrolled attenuation parametertransient elastography

Substanzen

Anti-HIV AgentsTenofovirAspartate Aminotransferases

Autor:innen und Institutionen

  • Department of Infectious Diseases and Clinical Microbiology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Türkiye.
  • Department of Infectious Diseases and Clinical Microbiology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Türkiye.
  • Department of Radiology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Türkiye.
  • Department of Gastroenterology, Istanbul University School of Medicine, Istanbul, Türkiye.
  • Department of Infectious Diseases and Clinical Microbiology, Basaksehir Cam & Sakura City Hospital, Istanbul, Türkiye.
  • Department of Infectious Diseases and Clinical Microbiology, Haseki Training and Research Hospital, Istanbul, Türkiye.

ORCID-Profile: Yusuf Emre Ozdemir, Bilgul Mete, Fehmi Tabak

Förderung

  • Istanbul Üniversitesi-Cerrahpasa

Zitieren

APA

Sahin Ozdemir, M., Ozdemir, Y. E., Dogdas, A., Nuriyev, K., Senkal, I. V., Gunduz, A., Zerdali, E., Kaymakoglu, S., Mete, B., & Tabak, F. (2026). The impact of cART on hepatic steatosis and fibrosis in treatment-naïve PLwHIV: A prospective cohort study. International Journal of STD & AIDS. https://doi.org/10.1177/09564624251382627

Vancouver

Sahin Ozdemir M, Ozdemir YE, Dogdas A, Nuriyev K, Senkal IV, Gunduz A, et al. The impact of cART on hepatic steatosis and fibrosis in treatment-naïve PLwHIV: A prospective cohort study. International Journal of STD & AIDS. 2026. doi:10.1177/09564624251382627

BibTeX
@article{SahinOzdemir2026,
  author = {Sahin Ozdemir, Meryem and Ozdemir, Yusuf Emre and Dogdas, Alperen and Nuriyev, Kanan and Senkal, Ibrahim Volkan and Gunduz, Alper and Zerdali, Esra and Kaymakoglu, Sabahattin and Mete, Bilgul and Tabak, Fehmi},
  title = {The impact of cART on hepatic steatosis and fibrosis in treatment-naïve PLwHIV: A prospective cohort study},
  journal = {International Journal of STD & AIDS},
  year = {2026},
  doi = {10.1177/09564624251382627}
}
Kostenlos starten →